Avita Medical Inc.

AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes

The PermeaDerm-I study met its primary endpoint, demonstrating a statistically significant 70% economic advantage over cadaveric allograft with a mean treatment cost of $148.70 per 1% TBSA compared to $497.10 for allograft. Clinical outcomes were comparable between groups, with approximately 94% of PermeaDerm patients achieving at least 95% graft take and all patients achieving 95% or greater wound healing by eight weeks. Additionally, the off-the-shelf nature of PermeaDerm reduced preparation time by 95.7% by eliminating the need for thawing and meshing, with no adverse events attributed to the product.

•2mo ago

AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven

AVITA Medical reported Q2 revenue of $21.7 million, up 18% year-over-year and 13% sequentially, driven by growth of its RECELL portfolio and operational discipline. Management raised full-year 2026 revenue guidance to $86 million-$89 million and confirmed expectations to reach cash flow breakeven in the fourth quarter of 2026. Net cash use improved to $3.2 million from $9.9 million in the prior quarter, supported by a gross margin of 81.9% and lower operating expenses.

•2mo ago

AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting

AVITA Medical presented positive data from the first U.K. case series using its RECELL GO automated cell harvesting device at the British Burn Association Annual Meeting. The study of 17 patients demonstrated successful outcomes in burn and reconstructive surgery, with investigators noting workflow benefits and reduced procedural variability compared to manual methods. Additionally, a separate systematic review of 99 studies covering over 8,000 patients reinforced the safety and efficacy of the RECELL platform across global markets.

•4mo ago

AVITA Medical Reports First Quarter 2026 Financial Results

AVITA Medical reported Q1 2026 revenue of $19.3 million, up 4% year-over-year and approximately 10% sequentially, driven by Cohealyx contributions and normalized RECELL utilization. Operating expenses fell 11% year-over-year to $24.5 million due to cost optimization initiatives, resulting in a net loss of $10.6 million ($0.35 per share), an improvement from the $13.9 million loss in Q1 2025. The company appointed Cary Vance as CEO and Jan Stern Reed as independent Board Chair, while reaffirming full-year 2026 revenue guidance of $80M-$85M. AVITA also secured a 10-year BARDA agreement valued at up to $25.5 million for burn emergency preparedness.

•5mo ago

AVITA Medical Names Cary Vance as Chief Executive Officer

AVITA Medical appointed interim CEO Cary Vance as permanent President and Chief Executive Officer, effective immediately. The Board simultaneously elected independent director Jan Stern Reed as its new Chair, replacing the prior lead independent director structure. Mr. Vance, who has led the company since October 2025, was credited with stabilizing the business and driving strategic focus during the transition period.

•6mo ago

AVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GO

AVITA Medical received TGA certification in Australia and Medsafe WAND listing in New Zealand for its RECELL GO system, enabling commercialization in both markets. The next-generation system automates the preparation of RECELL Spray-On Skin for burn and trauma wounds, capable of treating wounds up to 1,920 cm². Distribution partner Revolution Surgical expects to initiate the commercial launch within the coming weeks.

•6mo ago